Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / COM
-
Shares outstanding
-
63.6M
-
Number of holders
-
3
-
Total 13F shares, excl. options
-
80.3K
-
Shares change
-
-3.99K
-
Total reported value, excl. options
-
$3.69M
-
Value change
-
-$183K
-
Number of buys
-
2
-
Number of sells
-
-1
-
Price
-
$45.97
Significant Holders of RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) as of Q4 2023
3 filings reported holding RYTM - RHYTHM PHARMACEUTICALS, INC. - COM as of Q4 2023.
RHYTHM PHARMACEUTICALS, INC. - COM (RYTM) has 3 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 80.3K shares
of 63.6M outstanding shares and own 0.13% of the company stock.
Largest 10 shareholders include PRIMECAP MANAGEMENT CO/CA/ (8.05M shares), BAKER BROS. ADVISORS LP (6.4M shares), BlackRock Inc. (6.35M shares), RA CAPITAL MANAGEMENT, L.P. (5.33M shares), GOLDMAN SACHS GROUP INC (5.05M shares), VANGUARD GROUP INC (3.23M shares), NEA Management Company, LLC (2.91M shares), Frazier Life Sciences Management, L.P. (2.37M shares), FEDERATED HERMES, INC. (2.31M shares), and STATE STREET CORP (2.21M shares).
This table shows the top 3 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.